МОРФОЛОГИЧЕСКИЕ И УЛЬТРАСТРУКТУРНЫЕ ОСОБЕННОСТИ ДОФАМИНЕРГИЧЕСКИХ НЕЙРОНОВ КОМПАКТНОЙ ЧАСТИ ЧЁРНОЙ СУБСТАНЦИИ СРЕДНЕГО МОЗГА ПРИ БОЛЕЗНИ ПАРКИНСОНА: ОБЗОР ЛИТЕРАТУРЫ
DOI:
https://doi.org/10.5281/zenodo.24128109Keywords:
Parkinson’s disease, substantia nigra pars compacta, dopaminergic neurons, neuromelanin, α-synuclein, Lewy bodies, immunohistochemistry, ultrastructure, microgliaAbstract
Objective. To summarize published evidence on the morphological and ultrastructural features of dopaminergic neurons in the substantia nigra pars compacta (SNpc) in Parkinson’s disease. Materials and methods. A narrative analysis of scientific publications on light microscopy, immunohistochemistry, and electron microscopy was performed; no original morphological examinations were conducted. Results. The literature describes progressive loss of pigmented SNpc neurons, changes in neuromelanin and Nissl substance, pathological α-synuclein accumulation, and structural and functional alterations in mitochondria, the endoplasmic reticulum, and the autophagy–lysosomal system. Conclusions. Parkinson’s disease is associated with an interconnected pattern of neuronal, intracellular, and glial alterations; their combined assessment improves understanding of the structural basis of the disease.References
1. Braak, H. (2003). Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24(2), 197–211. https://doi.org/10.1016/S0197-4580(02)00065-9
2. Dickson, D. W. (2018). Neuropathology of Parkinson disease. Parkinsonism & Related Disorders. 2018;46(Suppl. 1):S30–S33. DOI: 10.1016/j.parkreldis.2017.07.033. 10.1016/j.parkreldis.2017.07.033. https://doi.org/10.1016/j.parkreldis.2017.07.033
3. Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017). Selective neuronal vulnerability with aging and in Parkinson’s disease. Nature Reviews Neuroscience, 18(2), 101–113. https://doi.org/10.1038/nrn.2016.178
4. Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A. E., & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers. 2017;3:17013. DOI: 10.1038/nrdp.2017.13. https://doi.org/10.1038/nrdp.2017.13
5. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–840. DOI: 10.1038/42166.
6. Wakabayashi, K., Tanji, K., Mori, F., & Takahashi, H. (2007). The Lewy body in Parkinson’s disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology, 27(5), 494–506. https://doi.org/10.1111/j.1440-1789.2007.00803.x
7. Bendor, J. T., Logan, T. P., & Edwards, R. H. (2013). The function of α-synuclein. Neuron, 79(6), 1044–1066. https://doi.org/10.1016/j
8. Michel, P. P., Hirsch, E. C., & Hunot, S. (2016). Understanding dopaminergic cell death pathways in Parkinson disease. Neuron, 90(4), 675–691. https://doi.org/10.1016/j.neuron.2016.03.038
9. Sulzer, D., Cassidy, C., Horga, G., et al. (2018). Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease. NPJ Parkinson’s Disease. 2018;4:11. DOI: 10.1038/s41531-018-0047-3. 41531–018. https://doi.org/10.1038/s41531-018-0047-3
10. Dickson, D. W. (2012). Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harbor Perspectives in Medicine. 2012;2(8):a009258. DOI: 10.1101/cshperspect.a009258. https://doi.org/10.1101/cshperspect.a009258
11. Kuusisto, E., Salminen, A., & Alafuzoff, I. (2001). Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport, 12(10), 2085–2090. https://doi.org/10.1097/00001756-200107200-00009
12. Schapira, A. H., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990). Mitochondrial complex I deficiency in Parkinson’s disease. Journal of Neurochemistry, 54(3), 823–827. https://doi.org/10.1111/j.1471-4159.1990.tb02325.x
13. Fujiwara, H., Hasegawa, M., Dohmae, N., et al. (2002). α-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology, 4(2), 160–164. https://doi.org/10.1038/ncb748
14. Choong, C. J., & Mochizuki, H. (2022). Neuropathology of α-synuclein in Parkinson’s disease. Neuropathology, 42(2), 93–103. https://doi.org/10.1111/neup.12812
15. Hirsch, E. C., & Hunot, S. (2009). Neuroinflammation in Parkinson’s disease: a target for neuroprotection? The Lancet Neurology. 10.1016/S1474-4422(09)70062-6. https://doi.org/10.1016/S1474-4422(09)70062-6
16. McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology, 38(8), 1285–1291. https://doi.org/10.1212/WNL.38.8.1285
17. Ahrorov, A. A., & Toshpulatov, S. S. (2026). Parkinson kasalligida mikrogliya hujayralarining morfofunksional transformatsiyasi va dopaminergik neyronlar degeneratsiyasi o‘rtasidagi patogenetik bog‘liqlik (adabiyotlar sharhi). Ёш олимлар тиббиёт журнали. 2026;(19):53–61. URL: https://journals.tnmu.uz/index.php/yotj/article/view/6306. https://journals.tnmu.uz/index.php/yotj/article/view/6306.
18. Mandel, S. A., Morelli, M., Halperin, I., & Korczyn, A. D. (2010). Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy. EPMA Journal, 1(2), 273–292. https://doi.org/10.1007/s13167-010-0036-z
19. Lynch, P. J. (n.d.). Brain human sagittal section.svg. Wikimedia Commons. CC BY 2.5. URL: https://commons.wikimedia.org/ wiki/File:Brain_human_sagittal_section.svg.

